We report the first documented case, to our knowledge, of a vitreo-retinal metastasis from a urogenital primary source.

Case Report {#s1}
===========

A 55-year-old man presented with a 3-month history of increasing floaters without photopsias. Systemic review of systems was positive for anorexia, night sweats, and fatigue. Medical history was significant for chronic hepatitis C, hemochromatosis, and high-grade urothelial carcinoma of the bladder treated with cystoprostatectomy with ureteroileal conduit 4 years earlier. Histopathologic analysis of the bladder tumor demonstrated invasion of the muscularis mucosae but not the muscularis propria with 1/11 + nodes (Stage T1N1M0). The patient received adjuvant chemotherapy with four cycles of carboplatin and Taxol.

Visual acuity on presentation was 20/20-1 in the right eye and 20/20-1 in the left eye. Anterior segment biomicroscopy revealed 1+ anterior chamber cells and a few keratic precipitates in the right eye. There were 2 to 3+ retrolental and mid-vitreous cells with snowballs and debris inferiorly. The optic nerve and macula appeared normal. An elevated white, vascularized lesion was present in the inferonasal retinal periphery with surrounding subretinal fluid and satellite lesions (Figure [1](#F1){ref-type="fig"}A). Examination of the left eye was normal.

![Initial clinical features. **A.** The amelanotic fundus mass is remarkable for corkscrew vascularity. **B.** Intravenous fluorescein angiography demonstrates communication between retinal and tumor vasculature. **C.** Ultrasonography revealed retinal thickening and intravitreal and subretinal particulate material.](cabr-12-177-g001){#F1}

Intravenous fluorescein angiography showed neither cystoid macular edema nor vasculitis but demonstrated communication between the retinal and tumor vasculature (Figure [1](#F1){ref-type="fig"}B). B-scan ultrasonography revealed particulate matter in the vitreous cavity and subretinal space and an area of thickened retina (Figure [1](#F1){ref-type="fig"}C).

Differential diagnosis included retinal abscess, metastasis, and granuloma. Laboratory test reports including RPR, fluorescent treponemal antibody absorption, quantiferon gold, Toxoplasma immunoglobulins G and M, chest x-ray, Lyme titers, and blood cultures were negative. Computed tomographies of the brain and orbits, chest, abdomen, and pelvis were negative for metastatic disease.

A diagnostic vitrectomy was performed. Histopathologic examination of the vitreous sample revealed sheets and strands of vitreous with numerous dyscohesive cells that were round or oval with significant nuclear pleomorphism and rare mitotic figures. Signet ring cells that contained vacuoles of periodic acid Schiff (PAS), and alcian blue-positive mucin were identified. Immunohistochemical staining (IHC) of the nuclei of the tumor cells was intensely positive for transcription factor GATA3, which is specific for urothelial and breast carcinoma. The cells were also strongly immunoreactive for epithelial markers AE1/AE3 and CK7 and CK20. Coexpression of CK7 and CK20 is a characteristic feature of urothelial carcinoma and excludes breast carcinoma that is only positive for CK7.

S-100 protein showed mild cytoplasmic staining and leukocyte common antigen was negative. Sections from the patient\'s original bladder tumor were reviewed, and cells in the vitreous biopsy appeared to be identical (Figure [2](#F2){ref-type="fig"}).

![Histopathology. Sections from the patient\'s original bladder tumor (**A**) and cells in the vitreous biopsy (**B**) appear similar. Both are characterized throughout by dyscohesive cells with significant nuclear pleomorphism consistent with an anaplastic epithelial neoplasm. Arrow indicates "signet ring" cell.](cabr-12-177-g002){#F2}

Despite external beam radiation therapy (3,750 cGy in 15 fractional doses), the tumor burden increased causing pseudohypopyon, pseudo posterior subcapsular cataract, and dense vitreous opacification (Figure [3](#F3){ref-type="fig"}). Visual acuity declined to no light perception. Intraocular pressure was 22 mmHg. The blind, painful eye was enucleated one year after the onset of visual symptoms. Sections revealed mass of tumor cells in the retina (Figure [2](#F2){ref-type="fig"}) with no evidence of choroidal involvement. Uveal involvement was detected in the iris stroma and anterior pars plicata. The vitreous and the anterior chambers contained significant quantities of tumor (Figure [4](#F4){ref-type="fig"}).

![Tumor cell precipitation on the posterior surface of the lens (**A**) and in the anterior chamber (**B**) creates an appearance of pseudo posterior subcapsular cataract and pseudohypopyon.](cabr-12-177-g003){#F3}

![**A.** Detached retina in the enucleated eye is thickened and opacified by tumor. Bilobed hemorrhage on the outer surface corresponds to the structure noted on B-scan ultrasound. **B.** Histopathology discloses diffuse infiltration of retina by round, dyscohesive tumor cells identical to those comprising primary bladder cancer and retinal biopsy (Hematoxylin and eosin, ×50). **C.** Higher magnification of tumor cells shows significant nuclear pleomorphism and scattered mitotic figures (Hematoxylin and eosin, ×400). **D.** Tumor cells within retina and on the inner surface of internal limiting membrane are intensely immunoreactive to the cytokeratin marker CK7. Cells also stained with CK20 and GATA3 consistent with urothelial carcinoma (IHC for CK7, ×100).](cabr-12-177-g004){#F4}

Discussion {#s2}
==========

Bladder cancer is the second most common genitourinary malignancy, accounting for 7% of cancer in men and 3% in women.^[@R1]^ Approximately 90% of epithelial tumors are urothelial carcinomas arising from the transitional epithelium of the bladder. High-grade tumors tend to recur locally and have a propensity for invading the bladder wall musculature. The most common sites of metastasis are the lymph nodes, liver, lung, bone, adrenal glands, and intestine.^[@R1],[@R2]^ The 5-year survival rate from urothelial tumors confined to the epithelium is 94% (carcinoma in situ or Stage 0), but declines sharply to 40% with locally advanced (Stage III) disease. The 5-year survival for those with distant metastases is 5%.^[@R2]^

Ocular metastasis from urothelial carcinoma is extremely rare. Previously reported cases have identified tumors in the orbit or choroid.^[@R1],[@R3],[@R4]^ Choroidal metastasis carries a poor prognosis. Levecq et al^[@R3]^ identified a survival rate ranging from 2 months to 7 months. To our knowledge, this is the first reported case of vitreo-retinal metastasis of urothelial carcinoma.

Retinal metastases are rare tumors. A comprehensive case study from 1997 identifying 520 cases of ocular metastasis by the site of eye involvement reported that 88% of ocular metastases were choroidal, 9% were to the iris, and 2% were to the ciliary body, and none were vitreo-retinal.^[@R5]^ A review of the recent literature identified only 55 cases of metastatic retinal tumors. The most commonly identified primary tumors were cutaneous melanoma (30.9%), lung carcinoma (25.5%), breast carcinoma (18.2%), and gastrointestinal tumors (16.4%).^[@R6]^ The primary tumors were occult in 5.5% of cases. A recent case series of eight patients with retinal metastasis highlighted the poor prognosis for survival. Five of 8 patients (62.5%) died within one month of diagnosis of retinal metastasis.^[@R7]^

In summary, we report the first case of metastatic urothelial carcinoma of the retina and vitreous. Unlike previously reported ocular metastatic urothelial carcinomas and retinal metastatic tumors for which prognosis for survival is extremely poor, our patient remains well 23 months after presentation.
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